LAVA Therapeutics N.V. (LVTX) Financials
LVTX Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-09-30 | 117.5 million | 59.7 million |
2023-06-30 | 133.2 million | 63.8 million |
2023-03-31 | 156.3 million | 62.6 million |
2022-12-31 | 153.9 million | 61.6 million |
LVTX Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-09-30 | -7.9 million | 978187 |
2023-06-30 | -14.4 million | 1.7 million |
2023-03-31 | 38.7 million | 987546 |
2022-12-31 | 38.1 million | 972293 |
LVTX Net Income
No data available :(
LVTX Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-09-30 | 110.8 million | - | 1.3 million |
2023-06-30 | 122.2 million | - | 2.2 million |
2023-03-31 | 144.8 million | - | 2.3 million |
2022-12-31 | 142.6 million | - | 869269 |
LVTX Shares Outstanding
LVTX Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-09-30 | 6351 | 8.4 million | 3.0 million | - |
2023-06-30 | 243562 | 13.7 million | 4.0 million | - |
2023-03-31 | 288851 | 11.4 million | 4.0 million | - |
2022-12-31 | 284390 | 11.3 million | 4.0 million | - |
LVTX Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-09-30 | 56108 | 10586 |
2023-06-30 | 5.6 million | 2.6 million |
2023-03-31 | 2.9 million | 10.7 million |
2022-12-31 | 2.8 million | - |
LVTX
Price: $2.73
52 week price:
Earnings Per Share: -1.57 USD
P/E Ratio: -0.90
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Volume: 12191
Market Capitalization: 81.8 million